longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Vor BioPharma

VOR

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is 2.10, above the reasonable range, cheaper than 1.92% of the time in the past 1 years, and the industry ranks 12/601, the industry Median -2.44.

2.1xP/E
$22.32Stock price
$10.61Earnings per share
2.1xP/E
Stock price$22.32Earnings per share$10.61

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-0.23x
Typical range
-1.01x–-0.10x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GRFSUSGRIFOLS SA
9.64x42.44%$5.06B
ACADUSAcadia Pharma
12.12x73.45%$4.61B
PURRUSHyperliquid Strategies
8.65x85.25%$2.22B
AUPHUSAurinia Pharma
6.83x54.40%$2.15B
ADMAUSAdma Biologics
11.41x35.42%$1.93B
LKFTUSLakefront Biotherapeutics
2.62x115.23%$1.82B
VORUSVor BioPharma
2.10x89.77%$1.32B
ABUSUSArbutus Pharma
6.51x533.09%$996.51M
RIGLUSRigel Pharma
2.57x83.91%$828.64M
BVNRYUSBavarian Nordic A/S
3.30x--$790.38M
IRWDUSIronwood Pharma
5.17x715.55%$670.87M
QTTBUSQ32 Bio
9.84x162.23%$332.52M
AGENUSAgenus
3.51x--$322.35M
CUVLUSClinuvel Pharmaceuticals
12.98x--$297.52M
CGENUSCompugen
6.49x173.68%$228.29M
PLXUSProtalix Biotherap
11.31x400.00%$214.32M
VXRTUSVaxart
3.03x328.57%$116.74M
RLYBUSRallybio
2.01x131.45%$91.45M
FBIOUSFortress Biotech
0.80x3,742.86%$83.04M
SPROUSSpero Therap
8.91x390.00%$65.81M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.